PriceTargets.com logo

Myovant Sciences - MYOV Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $27.00
  • Forecasted Upside: 0.07%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$26.98 As of 03/9/2023 07:40 PM ET
▼ -0.01 (-0.04%)
Get New Myovant Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYOV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYOV

Analyst Price Target is $27.00
▲ +0.07% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Myovant Sciences in the last 3 months. The average price target is $27.00, with a high forecast of $27.00 and a low forecast of $27.00. The average price target represents a 0.07% upside from the last price of $26.98.

This chart shows the closing price for MYOV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Myovant Sciences. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/24/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$23.00 ➝ $27.00Low
10/24/2022Robert W. BairdDowngradeOutperform ➝ Neutral$20.00 ➝ $27.00Low
8/9/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$12.00 ➝ $23.00Low
7/28/2022The Goldman Sachs GroupBoost TargetNeutral$9.00 ➝ $10.00Low
4/13/2022SVB LeerinkLower TargetMarket Perform$19.00 ➝ $12.00High
4/13/2022Robert W. BairdLower Target$30.00 ➝ $20.00High
2/16/2022SVB LeerinkLower TargetMarket Perform$21.00 ➝ $19.00Low
1/5/2022SVB LeerinkLower TargetMarket Perform$23.00 ➝ $21.00High
10/27/2021SVB LeerinkLower TargetMarket Perform$24.00 ➝ $23.00Medium
9/9/2021SVB LeerinkInitiated CoverageMarket Perform$24.00High
8/25/2021JMP SecuritiesReiterated RatingBuyLow
8/20/2021The Goldman Sachs GroupInitiated CoverageNeutral$18.00Low
5/13/2021CitigroupLower TargetNeutral ➝ Neutral$30.00 ➝ $24.00Low
5/3/2021JPMorgan Chase & Co.Lower TargetOverweight$38.00 ➝ $32.00Low
2/12/2021SVB LeerinkLower TargetMarket Perform$28.00 ➝ $26.00Low
1/8/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$30.00 ➝ $28.00High
1/6/2021The Goldman Sachs GroupDowngradeBuy ➝ Neutral$30.00N/A
12/21/2020Robert W. BairdBoost TargetOutperform$24.00 ➝ $30.00Medium
8/12/2020SVB LeerinkLower TargetOutperform$29.00 ➝ $28.00Low
7/7/2020SVB LeerinkBoost TargetOutperform$27.00 ➝ $29.00High
6/23/2020Evercore ISIBoost TargetOutperform ➝ Positive$45.00 ➝ $55.00High
6/2/2020CitigroupBoost TargetNeutral$9.00 ➝ $20.00High
6/1/2020Evercore ISIBoost Target$30.00 ➝ $35.00Medium
6/1/2020JPMorgan Chase & Co.Boost TargetOverweight$19.00 ➝ $26.00High
5/19/2020SVB LeerinkLower TargetOutperform$28.00 ➝ $27.00High
2/10/2020CowenReiterated RatingBuyHigh
2/2/2020CitigroupInitiated CoverageBuy ➝ Neutral$15.00Medium
11/19/2019JMP SecuritiesReiterated RatingBuy$34.00Low
11/19/2019The Goldman Sachs GroupReiterated RatingPositive ➝ Buy$18.00 ➝ $20.00Medium
11/12/2019CowenReiterated RatingBuyHigh
10/25/2019The Goldman Sachs GroupSet TargetBuy$18.00N/A
9/6/2019CowenReiterated RatingBuyHigh
8/28/2019The Goldman Sachs GroupInitiated CoverageBuy$20.00High
8/19/2019SVB LeerinkInitiated CoverageOutperform$26.00High
5/30/2019CitigroupInitiated CoverageBuy$25.00High
4/11/2019Evercore ISIInitiated CoverageOutperformHigh
2/13/2019BarclaysUpgradeEqual Weight ➝ Overweight$22.00 ➝ $25.00High
2/11/2019JMP SecuritiesReiterated RatingBuy$25.00Low
11/19/2018CitigroupLower TargetBuy ➝ Buy$44.00 ➝ $42.00Medium
11/9/2018CowenReiterated RatingBuyHigh
10/26/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00Medium
(Data available from 9/30/2018 forward)

News Sentiment Rating

0.45 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/4/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/3/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Myovant Sciences logo
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $26.98
Low: $26.98
High: $27.00

50 Day Range

MA: $26.96
Low: $26.88
High: $26.99

52 Week Range

Now: $26.98
Low: $7.67
High: $27.06

Volume

2,256,000 shs

Average Volume

1,169,678 shs

Market Capitalization

$2.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Myovant Sciences?

The following Wall Street research analysts have issued stock ratings on Myovant Sciences in the last twelve months: Robert W. Baird, StockNews.com, and SVB Leerink LLC.
View the latest analyst ratings for MYOV.

What is the current price target for Myovant Sciences?

2 Wall Street analysts have set twelve-month price targets for Myovant Sciences in the last year. Their average twelve-month price target is $27.00, suggesting a possible upside of 0.1%. Robert W. Baird has the highest price target set, predicting MYOV will reach $27.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $27.00 for Myovant Sciences in the next year.
View the latest price targets for MYOV.

What is the current consensus analyst rating for Myovant Sciences?

Myovant Sciences currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MYOV, but not buy more shares or sell existing shares.
View the latest ratings for MYOV.

What other companies compete with Myovant Sciences?

Other companies that are similar to Myovant Sciences include Ultragenyx Pharmaceutical, Prothena, Akero Therapeutics, Madrigal Pharmaceuticals and Arrowhead Pharmaceuticals. Learn More about companies similar to Myovant Sciences.

How do I contact Myovant Sciences' investor relations team?

Myovant Sciences' physical mailing address is 11-12 ST. JAMES SQUARE SUITE 1 3RD FLOOR, LONDON X0, SW1Y 4LB. The company's listed phone number is 442074003351 and its investor relations email address is inve[email protected]. The official website for Myovant Sciences is www.myovant.com. Learn More about contacing Myovant Sciences investor relations.